444 related articles for article (PubMed ID: 16336497)
1. Effect of tegaserod on gut transit in male and female subjects.
Degen L; Petrig C; Studer D; Schroller S; Beglinger C
Neurogastroenterol Motil; 2005 Dec; 17(6):821-6. PubMed ID: 16336497
[TBL] [Abstract][Full Text] [Related]
2. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
[TBL] [Abstract][Full Text] [Related]
3. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects.
Degen L; Matzinger D; Merz M; Appel-Dingemanse S; Osborne S; Lüchinger S; Bertold R; Maecke H; Beglinger C
Aliment Pharmacol Ther; 2001 Nov; 15(11):1745-51. PubMed ID: 11683688
[TBL] [Abstract][Full Text] [Related]
4. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
Morganroth J; Rüegg PC; Dunger-Baldauf C; Appel-Dingemanse S; Bliesath H; Lefkowitz M
Am J Gastroenterol; 2002 Sep; 97(9):2321-7. PubMed ID: 12358251
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial: effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia.
Thumshirn M; Fruehauf H; Stutz B; Tougas G; Salter J; Fried M
Aliment Pharmacol Ther; 2007 Nov; 26(10):1399-407. PubMed ID: 17892526
[TBL] [Abstract][Full Text] [Related]
6. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
[TBL] [Abstract][Full Text] [Related]
7. Tegaserod for the treatment of constipation-predominant irritable bowel syndrome.
Baker DE
Rev Gastroenterol Disord; 2001; 1(4):187-98. PubMed ID: 12120185
[TBL] [Abstract][Full Text] [Related]
8. Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.
Houghton LA; Atkinson W; Whorwell PJ; Morris J; Murdoch RD; Cooper SM; Webber DM; Walls CM
Clin Ther; 2006 Apr; 28(4):569-81. PubMed ID: 16750468
[TBL] [Abstract][Full Text] [Related]
9. Omeprazole-induced slowing of gastrointestinal transit in mice can be countered with tegaserod.
Cowan A; Earnest DL; Ligozio G; Rojavin MA
Eur J Pharmacol; 2005 Jul; 517(1-2):127-31. PubMed ID: 15972210
[TBL] [Abstract][Full Text] [Related]
10. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study.
Esfandyari T; Camilleri M; Ferber I; Burton D; Baxter K; Zinsmeister AR
Neurogastroenterol Motil; 2006 Sep; 18(9):831-8. PubMed ID: 16918762
[TBL] [Abstract][Full Text] [Related]
11. Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans.
Bouras EP; Burton DD; Camilleri M; Stephens DA; Thomforde GM
Neurogastroenterol Motil; 2004 Dec; 16(6):729-35. PubMed ID: 15601422
[TBL] [Abstract][Full Text] [Related]
12. Increased colonic transit in rats produced by a combination of a cholinesterase inhibitor with a 5-HT4 receptor agonist.
Campbell-Dittmeyer K; Hicks GA; Earnest DL; Greenwood-Van Meerveld B
Neurogastroenterol Motil; 2009 Nov; 21(11):1197-e108. PubMed ID: 19210632
[TBL] [Abstract][Full Text] [Related]
13. Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects.
Bharucha AE; Seide B; Guan Z; Andrews CN; Zinsmeister AR
Neurogastroenterol Motil; 2008 Jun; 20(6):643-8. PubMed ID: 18312543
[TBL] [Abstract][Full Text] [Related]
14. [Effects of various prokinetic drugs on gastrointestinal transit times in patients with progressive systemic scleroderma].
Folwaczny C; Läritz M; Meurer M; Endres SP; König A; Schindlbeck N
Z Gastroenterol; 1997 Oct; 35(10):905-12. PubMed ID: 9432812
[TBL] [Abstract][Full Text] [Related]
15. Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia.
Miner PB; Rodriguez-Stanley S; Proskin HM; Kianifard F; Bottoli I
Curr Med Res Opin; 2008 Aug; 24(8):2159-72. PubMed ID: 18561877
[TBL] [Abstract][Full Text] [Related]
16. Effects of a 5-HT(4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH.
Tutuian R; Mainie I; Allan R; Hargreaves K; Agrawal A; Freeman J; Gale J; Castell DO
Aliment Pharmacol Ther; 2006 Jul; 24(1):155-62. PubMed ID: 16803614
[TBL] [Abstract][Full Text] [Related]
17. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.
Prather CM; Camilleri M; Zinsmeister AR; McKinzie S; Thomforde G
Gastroenterology; 2000 Mar; 118(3):463-8. PubMed ID: 10702196
[TBL] [Abstract][Full Text] [Related]
18. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study.
Kamm MA; Müller-Lissner S; Talley NJ; Tack J; Boeckxstaens G; Minushkin ON; Kalinin A; Dzieniszewski J; Haeck P; Fordham F; Hugot-Cournez S; Nault B
Am J Gastroenterol; 2005 Feb; 100(2):362-72. PubMed ID: 15667494
[TBL] [Abstract][Full Text] [Related]
19. Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod.
Tougas G; Earnest DL; Chen Y; Vanderkoy C; Rojavin M
Aliment Pharmacol Ther; 2005 Jul; 22(1):59-65. PubMed ID: 15963081
[TBL] [Abstract][Full Text] [Related]
20. Effect of atilmotin on gastrointestinal transit in healthy subjects: a randomized, placebo-controlled study.
Park MI; Ferber I; Camilleri M; Allenby K; Trillo R; Burton D; Zinsmeister AR
Neurogastroenterol Motil; 2006 Jan; 18(1):28-36. PubMed ID: 16371080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
